



EAPCI
European Association of
Percutaneous Cardiovascular
Interventions



ESC
European Society
of Cardiology

European Association of Percutaneous Cardiovascular Interventions

Professor Eric Van Belle
France

Application for the following position in the EAPCI Board 2020-2022:
SECRETARY

Current position

Professor - Head of Heart and Lung Institute, University Hospital, Lille, France
Chairman of the Education and Training Committee of the EAPCI
Director of the French Interventional Training Program – elected position
Member of the French Working Group in Interventional Cardiology (GACI) – elected position

Profession

- X Interventionalist
☐ Healthcare Professional (Nurse, Radiographer, Technician) working in PCI
☐ Industry Professional
☐ Other

Additional Information

- x Fellow of the ESC
x EAPCI Member
☐ Member of another ESC Association (beyond EAPCI)
If yes, specify:
x Active in an ESC Member Country
If yes, specify your country of work: France
x Member of a National Cardiac Society
If yes, specify: Société Française de Cardiologie (SFC) – French Society of Cardiology
x Member of an Interventional Working Group
If yes, specify: Groupe Athérome et Cardiologie Interventionnelle (GACI) – Interventional Working Group of the French Society of Cardiology

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

EDUCATION ACTIVITY

At the European Level, my education activities includes co-chairing (2016-2018) and chairing (2018-2020) the Education and Training Committee (ETC) of the EAPCI. Among other achievements, I have launched, together with Prof Dudek and Dr Teles, the new EAPCI certification in Interventional Cardiology (2018). I have also coordinated the redaction of the new "EAPCI Core Curriculum for Percutaneous Cardiovascular Intervention (2020)". Under my direction, the ETC of the EAPCI has now become the largest committee of the EAPCI involving > 30 individuals to ensure the representativity of the Interventional Working Groups of all European countries and to conduct the large amount of work of the committee.

At the national level, it includes the Direction of the French Interventional Cardiology Training Program since 2015. The first two years of the program are dedicated to coronary angiography and PCI. As part of my tenure, I have launched a 3rd year of training dedicated to structural disease and TAVI.

At Lille University, teaching activities include teaching in the general medical program, in the cardiology (specialty) program as well as in the basic science program (Master).

SCIENTIFIC INTERESTS

Research interests include basics and clinical aspects of the outcome of high risk population such as diabetics and post-MI patients following percutaneous coronary interventions (PCI), the use of biomarkers and invasive physiology (FFR, iFR) for risk prediction and therapeutic stratification at the time of PCI. More recently it included also the optimization of transcatheter aortic valve intervention (TAVI), in particular the use of pre-procedural imaging and biology to understand the role post-procedural aortic regurgitation. This scientific activity led to the publication of more than 200 publications in international scientific journals with a total "H" index of 57.

CLINICAL ACTIVITY

Clinical activities focus on prevention and treatment of complications of coronary atherosclerosis and Heart Valve Disease. It includes the management of a catheterization laboratory including 3 rooms and performing 4000 catheterization/year and 360 transcatheter aortic valve intervention (TAVI)/year (CHU Lille). Personal activity in percutaneous coronary interventions (PCI) is 200-250 cases/year for the last 25 years and TAVI is 70-100 cases/ year for the last 10 years.

MANAGEMENT

Medical Direction of the Heart and Lung Institute (500 beds) at the Lille University Hospital, France.

Previous experience in EAPCI, ESC or your National Bodies

Specifically, please indicate if you hold an Executive position (President, Vice President, President Elect) in a National Cardiac Society or in the ESC. If so, please indicate which one as well as the term of this position.

EAPCI: Co-chair of the Education and Training Committee (2016-2018)

EAPCI: Chair of the Education and Training Committee (2018-2020)

France: Director of the National Training Programme in Interventional Cardiology (Since 2015) – elected position

France: Member of the board of the working group in interventional cardiology (GACI): 2012 -2016 – elected position

France: Member of the board of the working group in interventional cardiology (GACI): 2020 -2022 – elected position

If you have been involved in EAPCI in the past, please specify the position(s) as well as the relevant date(s)

In particular, please indicate if you served in:

- | | |
|--|-----|
| • EAPCI Board 2018-2020 (under A. Baumbach's leadership)? | Yes |
| • EAPCI Board 2016-2018 (under M. Haude's leadership)? | Yes |
| • EAPCI Board 2014-2016 (under S. Windecker's leadership)? | No |
| • EAPCI Board 2011-2014 (under J. Fajadet's leadership)? | No |
| • EAPCI Board 2009-2011 (under C. Di Mario's leadership)? | No |
| • EAPCI Board 2006-2009 (under W. Wijns' leadership)? | No |

If you answered yes to at least one of these questions, please provide details.

EAPCI Board 2018-2020: Chairman of the Education and Training Committee

EAPCI Board 2016-2018: Co-Chairman of the Education and Training Committee

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

Publications in the field of PCI (most important 10 publications)

1. Van Belle E, Cosenza A, Baptista SB, Vincent F, Henderson J, Santos L, Rioufol G, Ramos R, Pouillot C, Calé R, Cuisset T, Jorge E, Teiger E, Machado C, Belle L, Costa M, Barreau D, Oliveira E, Hanssen M, Costa J, Besnard C, Nunes L, Dallongeville J, Sideris G, Bretelle C, Fonseca N, Lhoest N, Guardado J, Silva B, Sousa MJ, Barnay P, Silva JC, Leborgne L, Rodrigues A, Porouchani S, Seca L, Fernandes R, Dupouy P and Raposo R; for the PRIME-FFR study group. Reliability of routine fractional flow reserve for clinical management of coronary artery disease in patients with diabetes. JAMA Cardiol. Published online January 2, 2020. doi:10.1001/jamacardio.2019.5097
2. Van Belle E, Vincent F, Labreuche J, Auffret V, Debry N, Lefevre T, Eltchaninoff H, Manigold T, Gilard M, Verhoye JP, Himbert D, Koning R, Collet JP, Leprince P, Teiger E, Duhamel A, Cosenza A, Schurtz G, Porouchani S, Lattuca B, Robin E, Coisne A, Modine T, Richardson M, Joly P, Rioufol G, Ghostine S, Bar O, Amabile N, Champagnac D, Ohlmann P, Meneveau N, Lhermusier T, Leroux L, Leclercq F, Gandet T, Pinaud F, Cuisset T, Motreff P, Souteyrand G, Iung B, Folliguet T, Commeau P, Cayla G, Bayet G, Darremont O, Spaulding C, Le Breton H, Delhay C. Balloon-Expandable versus Self-Expanding Transcatheter Aortic Valve Replacement: A Propensity-Matched Comparison from The France-TAVI Registry. Circulation. 2019 Nov 16. doi: 10.1161/CIRCULATIONAHA.119.043785. [Epub ahead of print]
3. Modine T, Vahl TP, Khalique OK, Coisne A, Vincent F, Montaigne D, Godart F, Van Belle E, Granada JF. First-in-Human Implant of the Cephea Transseptal Mitral Valve Replacement System. Circ Cardiovasc Interv. 2019 Sep;12(9):e008003. doi: 10.1161/CIRCINTERVENTIONS.119.008003. Epub 2019 Sep 12. No abstract available.
4. Van Belle E, Vincent F, Rauch A, Casari C, Jeanpierre E, Loobuyck V, Rosa M, Delhay C, Spillemaeker H, Paris C, Debry N, Verdier B, Vincentelli A, Dupont A, Lenting PJ, Susen S. von Willebrand Factor and Management of Heart Valve Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2019 Mar 12;73(9):1078-1088. doi: 10.1016/j.jacc.2018.12.045. Review.
5. Van Belle E, Vincent F, Raposo L, Bravo Baptista S, Dupouy P. Reclassification of Treatment Strategy by Routine Coronary Pressure Assessment-Episode 7 of the Saga: The More You Look, the More You Find It! JACC Cardiovasc Interv. 2018 Oct 22;11(20):2095-2098. doi: 10.1016/j.jcin.2018.09.002. No abstract available.
6. Vincent F, Rauch A, Spillemaeker H, Vincentelli A, Paris C, Rosa M, Dupont A, Delhay C, Verdier B, Robin E, Lenting PJ, Susen S, Van Belle E. Real-Time Monitoring of von Willebrand Factor in the Catheterization Laboratory: The Seatbelt of Mini-Invasive Transcatheter Aortic Valve Replacement? JACC Cardiovasc Interv. 2018 Sep 10;11(17):1775-1778. doi: 10.1016/j.jcin.2018.05.047. Review.
7. Van Belle E, Gil R, Klauss V, Balghith M, Meuwissen M, Clerc J, Witzensbichler B, Cercek M, Vlachojannis M, Lang I, Commeau P, Vincent F, Testa L, Wasek W, Debry N, Kische S, Gabrielli G, Sardella G. Impact of Routine Invasive Physiology at Time of Angiography in Patients With Multivessel Coronary Artery Disease on Reclassification of Revascularization Strategy: Results From the DEFINE REAL Study. JACC Cardiovasc Interv. 2018 Feb 26;11(4):354-365. doi: 10.1016/j.jcin.2017.11.030.

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

8. Van Belle E, Baptista SB, Raposo L, Henderson J, Rioufol G, Santos L, Pouillot C, Ramos R, Cuisset T, Calé R, Teiger E, Jorge E, Belle L, Machado C, Barreau D, Costa M, Hanssen M, Oliveira E, Besnard C, Costa J, Dallongeville J, Pipa J, Sideris G, Fonseca N, Bretelle C, Guardado J, Lhoest N, Silva B, Barnay P, Sousa MJ, Leborgne L, Silva JC, Vincent F, Rodrigues A, Seca L, Fernandes R, Dupouy P; PRIME-FFR Study Group. Impact of Routine Fractional Flow Reserve on Management Decision and 1-Year Clinical Outcome of Patients With Acute Coronary Syndromes: PRIME-FFR (Insights From the POST-IT [Portuguese Study on the Evaluation of FFR-Guided Treatment of Coronary Disease] and R3F [French FFR Registry] Integrated Multicenter Registries - Implementation of FFR [Fractional Flow Reserve] in Routine Practice). *Circ Cardiovasc Interv.* 2017 Jun;10(6). pii: e004296. doi: 10.1161/CIRCINTERVENTIONS.116.004296.
9. Van Belle E, Rauch A, Vincent F, Robin E, Kibler M, Labreuche J, Jeanpierre E, Levade M, Hurt C, Rousse N, Dally JB, Debry N, Dallongeville J, Vincentelli A, Delhay C, Auffray JL, Juthier F, Schurtz G, Lemesle G, Caspar T, Morel O, Dumonteil N, Duhamel A, Paris C, Dupont-Prado A, Legendre P, Mouquet F, Marchant B, Hermoire S, Corseaux D, Moussa K, Manchuelle A, Bauchart JJ, Loobuyck V, Caron C, Zawadzki C, Leroy F, Bodart JC, Staels B, Goudemand J, Lenting PJ, Susen S. Von Willebrand Factor Multimers during Transcatheter Aortic-Valve Replacement. *N Engl J Med.* 2016 Jul 28;375(4):335-44. doi: 10.1056/NEJMoa1505643.
10. Van Belle E, Hengstenberg C, Lefevre T, Kupatt C, Debry N, Husser O, Pontana F, Kuchcinski G, Deliargyris EN, Mehran R, Bernstein D, Anthopoulos P, Dangas GD; BRAVO-3 MRI Study Investigators. Cerebral Embolism During Transcatheter Aortic Valve Replacement: The BRAVO-3 MRI Study. *J Am Coll Cardiol.* 2016 Aug 9;68(6):589-599. doi: 10.1016/j.jacc.2016.05.006. Epub 2016 May 18.

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

What would you like to achieve if you were elected? Please provide your 3 main topics (max 500 words)

- To further develop the interaction of the EAPCI with other European and international societies and working groups, using a network approach in which EAPCI should be the cornerstone.
- To expand educational programs for young interventionalists at the European level - taking into account the recent changes in the scope of the practice, in particular the development of interventional cardiology for structural heart disease.
- To position EAPCI as a main contender in the discussion between the Cardiology community and our European surgical colleagues, with the goal to defend the vision of our community in the increasing development of the heart-team approach both for patients with coronary artery disease and those with valvular or structural heart disease.

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

If you were elected, how do you envisage to organize yourself to accommodate this very time demanding additional commitment?

One full day a week will be dedicated to this activity.

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

Personal Data Privacy (please tick the relevant box to confirm consent)

The information collected is subject to data processing and storage. The recipients of the data are:

- *The internal ESC / EAPCI staff responsible for the organization of the elections*
- *EAPCI Nominating Committee 2018-2020*
- *EAPCI Voting members, during the e-voting*
- *Visitors Website*
- *National Cardiac Societies and Interventional Working Groups*

Your data will only be used to make a list of candidates to the 2020-2022 Board elections to be reviewed by the EAPCI Nominating Committee 2018-2020 and then posted on the ESC website and made available through the electronic voting platform. All data are mandatory as part of the election process.

Your data will be kept by ESC for a duration of 4 years.

X I give my consent on the use and transfer of my personal data as detailed above

In accordance with the chapter 3 of the European Regulation 2016/679 with regards to data protection, you have the right to request from ESC, access to and rectification or erasure of your personal data or restriction of processing concerning your data or to object to processing as well as the right to data portability. For such, please contact (together with a proof of identity):

*Data Privacy
European Society of Cardiology
Les Templiers
2035 Route des Colles
CS 80179 Biot
06903 SOPHIA ANTIPOLIS CEDEX, France*

Or by email to dataprivacy@escardio.org.

You have the right to lodge a complaint with a supervisory authority, and for information, ESC has appointed a Data Protection Officer that you can reach at dpo@escardio.org.

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.